Which combination is often used to extend levodopa's effect in Parkinson's disease therapy?

Prepare for the EDAPT Intracranial Regulation Test with interactive flashcards and multiple choice questions. Each question is accompanied by helpful hints and explanations to boost your readiness. Get started today and ensure your success!

Multiple Choice

Which combination is often used to extend levodopa's effect in Parkinson's disease therapy?

Explanation:
Extending levodopa’s effect relies on blocking its peripheral breakdown so more drug reaches the brain and stays active longer. A COMT inhibitor does exactly this by preventing levodopa from being converted to 3-O-methyllevodopa in the periphery, which increases the amount that enters the brain and smooths motor fluctuations. Tolcapone, as a COMT inhibitor, is commonly added to levodopa therapy to prolong its central effect and reduce wearing-off, though it requires liver function monitoring due to potential toxicity. Other options involve different mechanisms (MAO-B inhibition, NMDA antagonism, or peripheral decarboxylase inhibition) and don’t extend levodopa’s duration in the same way.

Extending levodopa’s effect relies on blocking its peripheral breakdown so more drug reaches the brain and stays active longer. A COMT inhibitor does exactly this by preventing levodopa from being converted to 3-O-methyllevodopa in the periphery, which increases the amount that enters the brain and smooths motor fluctuations. Tolcapone, as a COMT inhibitor, is commonly added to levodopa therapy to prolong its central effect and reduce wearing-off, though it requires liver function monitoring due to potential toxicity. Other options involve different mechanisms (MAO-B inhibition, NMDA antagonism, or peripheral decarboxylase inhibition) and don’t extend levodopa’s duration in the same way.

More Multiple Choice Questions
Subscribe

Get the latest from Passetra

You can unsubscribe at any time. Read our privacy policy